Key Takeaways BIIB teams up with Dayra to discover and develop oral macrocyclic peptides for immunological targets.The collaboration leverages Dayra's platform to identify and optimize candidates that BIIB may advance.BIIB will pay $50M upfront and may make milestone payments as it builds its immunology pipeline.Biogen (BIIB) announced the signing of a research collaboration agreement with privately held Dayra Therapeutics to discover and develop oral macrocyclic peptides for priority targets in immunologic ...

Core Insights - Versant Ventures has launched Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for serious diseases [1] - The company has secured over $70 million in committed funding, including a $50 million upfront capital collaboration with Biogen Inc. [1] - Dayra Therapeutics emerged from Versant's Frontier Discovery Engine, which operates in Toronto and Montreal [1]